AstraZeneca PLC and Fudan University to Collaborate on Cardiovascular Disease

by Richard Daverman, PhD

December 19, 2012 -- AstraZeneca will collaborate with Fudan University to discover the mechanism behind leonurine, a TCM product derived from Herba Leonuri that is used to treat heart disease, ischemic stroke and atherosclerosis. AstraZeneca will underwrite the cost of two years of research with the hope of discovering a new treatment for the diseases. More details....

Stock Symbol: (NYSE: AZN)

Back to news